Afuco™ Anti-Human HCV ADCC Therapeutic Antibody (MBL-HCV1), ADCC Enhanced
Anti-HCV ADCC Enhanced Antibody (MBL-HCV1) is an ADCC enhanced antibody produced by our Afuco™ platform. This is a human monoclonal antibody targeting the HCV E2 glycoprotein (MBL-HCV1) delays HCV viral rebound following liver transplantation. As with other HCV monotherapies, antibody-treated subjects had resistance-associated variants at the time of viral rebound. A combination study of MBL-HCV1 with a direct-acting antiviral is underway.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-329CL |
| Pricing | Inquiry |
| Host | Human |
| Target | HCV |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | 4°C or -20°C, avoid repeated freezing and thawing. |